Helixmith is a gene therapy company headquartered in Seoul, Korea, developing new and innovative biopharmaceuticals for previously untreated diseases, and is listed on KOSDAQ. The company has an extensive gene therapy pipeline, including a CAR-T program targeting several different types of solid tumors and an AAV vector program targeting neuromuscular diseases. Engensis (VM202), a more advanced pipeline candidate, is a plasmid DNA therapy being studied for DPN, diabetic foot ulcers, claudication, amyotrophic lateral sclerosis (Phase 2 beginning in late 2020), coronary artery disease and Charcot-Marie-Tooth disease. Helixmith clinical development activities are based in San Diego, California,
| Website | https://www.helixmith.com/ |
| Employees | 26 (14 on RocketReach) |
| Founded | 1996 |
| Phone | +1 858-922-2045 |
| Technologies |
JavaScript
,
HTML
,
Font Awesome
+6 more
(view full list)
|
| Industry | Biotechnology, Manufacturing General, Manufacturing |
| Keywords | Gene Therapy, Cell Therapy, Innovative Medicines, Genetic Engineering, Pharmaceutical Research, Biotechnology, Drug Development, Pharmaceutical, Clinical Trials, Therapeutics, New Treatments, Health, Disease Treatment, Medicine, Rare Diseases, Research, Treatment |
| Competitors | Novartis, Pfizer, AstraZeneca, Bristol Myers Squibb, Genentech, Amgen, Regeneron, Gilead Sciences, Vertex Pharmaceuticals, Lilly India +37 more (view full list) |
| SIC | SIC Code 283 Companies, SIC Code 28 Companies, SIC Code 80 Companies |
| NAICS | NAICS Code 325 Companies, NAICS Code 3254 Companies, NAICS Code 32 Companies |
Looking for a particular Helixmith employee's phone or email?
John Carlins is the Sr. Director Clinical Operations of Helixmith.
14 people are employed at Helixmith.
The NAICS codes for Helixmith are [325, 3254, 32].
The SIC codes for Helixmith are [283, 28, 80].